NASDAQ:MLTX MoonLake Immunotherapeutics Q3 2025 Earnings Report $17.80 -0.20 (-1.11%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$17.64 -0.16 (-0.87%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPS-$1.10Consensus EPS -$0.89Beat/MissMissed by -$0.21One Year Ago EPS-$0.56MoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:00PM ETUpcoming EarningsMoonLake Immunotherapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) MoonLake Immunotherapeutics Earnings HeadlinesMoonLake shareholders back director, auditor and compensation plansJune 9 at 6:11 PM | tipranks.comWhy did MLTX stock rise after-hours today?June 8 at 10:49 PM | msn.comHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategist at The Oxford Club, AI is doubling in power every 6 months - and the implications for investors are staggering. Green warns that holding the leading AI stocks could be the wrong move as this shift accelerates. With 41 years of market experience, he says a rare window is open right now - but not for long.June 10 at 1:00 AM | The Oxford Club (Ad)MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis SuppurativaJune 8 at 12:31 PM | tipranks.comHead to Head Analysis: Acurx Pharmaceuticals (NASDAQ:ACXP) versus MoonLake Immunotherapeutics (NASDAQ:MLTX)June 6, 2026 | americanbankingnews.comMoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressJune 2, 2026 | insidermonkey.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?Has Temu-Owner PDD's Story Changed After Double Miss?Campbell's Soup Stock: Deep Value and a 7% Dividend YieldTanker Dividends Are Surging, But Income Investors Need to Watch the CycleCybersecurity Earnings: 1 AI Standout and 2 Stocks Under PressureThese 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Upcoming Earnings Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
